Goldman Sachs
PACB icon

Goldman Sachs’s Pacific Biosciences PACB Stock Holding History

Goldman Sachs’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-75,000
Closed -$985K – 7251
2015
Q4 		$985K Buy
+75,000
New +$673K ﹤0.01% 4312

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's PACB Position: Q1 2026 in Review

Goldman Sachs reduced its Pacific Biosciences (PACB) stake by 28% in Q1 2026, selling an estimated $698K and leaving 988,467 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4896.

Goldman Sachs first reported a position in PACB in Q3 2013 and has held it in 51 quarters since. The position peaked at $91.9M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Goldman Sachs held 988,467 shares of Pacific Biosciences worth $1.3M as of Q1 2026.
  • Goldman Sachs sold 390,405 Pacific Biosciences shares in Q1 2026, an estimated $698K.
  • Pacific Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4896 holding.
  • Goldman Sachs first reported a position in Pacific Biosciences in Q3 2013 and has held it in 51 quarters since.
  • Goldman Sachs's Pacific Biosciences position peaked at $91.9M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.